
  
    
      
        Background_NNP
        
          Lead-time_NNP bias_NN
          Detection_NNP of_IN an_DT asymptomatic_JJ cancer_NN by_IN screening_VBG
          starts_VBZ the_DT clock_NN at_IN a_DT younger_JJR age_NN so_IN the_DT survival_NN time_NN
          from_IN screen_NN detection_NN is_VBZ longer_RBR than_IN the_DT survival_NN time_NN
          from_IN clinical_JJ detection_NN ,_, even_RB if_IN screening_NN does_VBZ not_RB
          change_VB the_DT age_NN of_IN death_NN ._. As_IN an_DT analogy_NN ,_, imagine_VB waiting_VBG
          at_IN a_DT bus_NN stop_NN C_NNP for_IN a_DT bus_NN traveling_VBG north_RB to_TO destination_NN
          D_NNP ._. Suppose_VB you_PRP walk_VB south_RB and_CC board_VB the_DT same_JJ bus_NN at_IN stop_NN
          B_NNP prior_RB to_TO its_PRP$ arrival_NN at_IN C_NNP ._. Although_IN the_DT bus_NN ride_NN from_IN B_NNP
          to_TO D_NNP is_VBZ longer_RBR than_IN from_IN C_NNP to_TO D_NNP (_( by_IN the_DT lead_JJ time_NN from_IN B_NNP
          to_TO C_NNP )_) ,_, the_DT arrival_NN time_NN at_IN D_NNP is_VBZ unchanged_JJ ._. You_PRP have_VBP
          simply_RB spent_VBN more_JJR of_IN your_PRP$ life_NN on_IN the_DT bus_NN ._. The_DT travel_NN
          time_NN from_IN B_NNP to_TO D_NNP is_VBZ a_DT lead-time-biased_JJ estimate_NN of_IN the_DT
          travel_NN time_NN from_IN C_NNP to_TO D_NNP ._.
        
        
          Length-bias_NNP
          Screening_NNP preferentially_RB detects_NNS slower_JJR growing_VBG
          cancers_NNS because_IN there_EX is_VBZ a_DT longer_JJR period_NN of_IN time_NN (_( hence_RB
          the_DT name_NN length-bias_JJ )_) when_WRB such_JJ cancers_NNS could_MD be_VB found_VBN on_IN
          screening_NN ._. If_IN slower_JJR growing_VBG cancers_NNS have_VBP a_DT different_JJ
          prognosis_NN than_IN faster_JJR growing_VBG cancers_NNS ,_, the_DT estimated_VBN
          survival_NN time_NN after_IN diagnosis_NN will_MD be_VB subject_JJ to_TO
          length-bias_JJ ._. Continuing_VBG with_IN the_DT analogy_NN ,_, suppose_VBP there_EX
          are_VBP two_CD types_NNS of_IN buses_NNS :_: slow_JJ local_JJ buses_NNS that_WDT frequently_RB
          stop_VB at_IN B_NNP ,_, and_CC fast_RB express_VB buses_NNS that_WDT rarely_RB stop_VB at_IN B_NNP ._.
          Because_IN a_DT bus_NN boarded_JJ at_IN B_NNP is_VBZ most_RBS likely_JJ local_NN ,_, the_DT
          average_JJ time_NN it_PRP takes_VBZ to_TO travel_VB from_IN C_NNP to_TO D_NNP (_( thus_RB the_DT
          lead_JJ time_NN has_VBZ been_VBN subtracted_VBN )_) will_MD be_VB a_DT length-biased_JJ
          estimate_NN of_IN the_DT averages_NNS of_IN the_DT local_JJ and_CC express_VB travel_NN
          times_NNS from_IN C_NNP to_TO D_NNP ._.
        
        
          Overdiagnosis_NNP bias_NN
          Screening_NNP may_MD detect_VB cancers_NNS that_WDT would_MD never_RB surface_VB
          clinically_RB or_CC be_VB diagnosed_VBN in_IN the_DT absence_NN of_IN screening_NN ._.
          Continuing_VBG with_IN the_DT analogy_NN ,_, suppose_VBP some_DT buses_NNS stop_VBP at_IN B_NNP
          but_CC not_RB D_NNP ._. Overdiagnosis_NNP bias_NN arises_VBZ when_WRB counting_VBG all_DT
          buses_NNS stopping_VBG at_IN B_NNP as_IN going_VBG to_TO D_NNP ._.
        
        
          Selection_NN bias_NN
          The_DT type_NN of_IN subject_JJ who_WP receives_VBZ screening_NN may_MD differ_VB
          from_IN other_JJ subjects_NNS in_IN ways_NNS that_WDT are_VBP related_VBN to_TO survival_NN
          times_NNS ._. Continuing_VBG with_IN the_DT analogy_NN ,_, suppose_VBP there_EX is_VBZ only_RB
          one_CD type_NN of_IN bus_NN (_( so_RB there_EX is_VBZ no_DT length-bias_JJ or_CC
          overdiagnosis_NNS bias_NN )_) ,_, but_CC you_PRP only_RB board_NN it_PRP at_IN stop_NN B_NNP in_IN
          the_DT morning_NN when_WRB the_DT traffic_NN is_VBZ heaviest_JJS ._. The_DT time_NN it_PRP
          takes_VBZ the_DT bus_NN boarded_JJ at_IN B_NNP to_TO travel_VB from_IN C_NNP to_TO D_NNP (_( so_RB
          lead-time_JJ has_VBZ been_VBN removed_VBN )_) is_VBZ a_DT selection-biased_JJ
          estimate_NN of_IN the_DT average_NN ,_, over_IN the_DT entire_JJ day_NN ,_, of_IN the_DT
          travel_NN times_NNS from_IN C_NNP to_TO D_NNP ._.
          A_DT randomized_JJ trial_NN with_IN an_DT endpoint_NN of_IN death_NN
          (_( typically_RB measured_VBN in_IN each_DT trial_NN arm_NN as_IN a_DT death_NN rate_NN
          among_IN all_DT participants_NNS )_) avoids_VBZ these_DT biases_NNS ._. Lead-time_NNP
          bias_NN is_VBZ avoided_VBN by_IN setting_VBG the_DT time_NN of_IN randomization_NN
          instead_RB of_IN the_DT time_NN of_IN cancer_NN detection_NN as_IN the_DT zero_CD time_NN ._.
          Length-bias_NNP and_CC overdiagnosis_NNS bias_NN are_VBP avoided_VBN because_IN
          the_DT comparison_NN is_VBZ between_IN randomized_JJ groups_NNS not_RB between_IN
          screen-detected_JJ and_CC clinically_RB detected_VBD cancer_NN cases_NNS ._. The_DT
          use_NN of_IN a_DT mortality_NN endpoint_NN also_RB avoids_VBZ lead-time_JJ bias_NN ,_,
          length-bias_JJ ,_, and_CC overdiagnosis_NNS bias_NN that_WDT would_MD arise_VB with_IN
          an_DT endpoint_NN based_VBN on_IN characteristics_NNS of_IN the_DT cancer_NN ._. For_IN
          example_NN ,_, suppose_VBP that_DT stage_NN were_VBD the_DT endpoint_NN of_IN the_DT
          trial_NN ._. A_DT screen-detected_JJ stage_NN I_PRP cancer_NN is_VBZ likely_JJ to_TO have_VB
          a_DT different_JJ prognosis_NN than_IN a_DT clinically_RB detected_VBN stage_NN I_PRP
          cancer_NN due_JJ to_TO lead-time_JJ ,_, length_NN ,_, and_CC overdiagnosis_NNS
          biases_NNS ._. Therefore_RB using_VBG stage_NN as_IN endpoint_NN would_MD bias_NN the_DT
          results_NNS ._.
          Selection_NN bias_NN within_IN the_DT trial_NN is_VBZ avoided_VBN because_IN
          randomization_NN guarantees_VBZ the_DT same_JJ distribution_NN of_IN known_VBN
          and_CC unknown_JJ covariates_NNS in_IN both_DT groups_NNS ._. Under_IN
          randomization_NN ,_, imbalances_NNS can_MD occur_VB in_IN the_DT empirical_JJ
          distribution_NN of_IN baseline_NN covariates_NNS ._. These_DT imbalances_NNS are_VBP
          not_RB generally_RB a_DT concern_NN unless_IN they_PRP are_VBP extremely_RB large_JJ
          even_RB after_IN adjusting_VBG for_IN multiple_JJ comparisons_NNS ._. In_IN that_DT
          case_NN one_PRP should_MD investigate_VB if_IN there_EX were_VBD any_DT deviation_NN
          from_IN random_JJ treatment_NN assignment_NN that_WDT may_MD have_VB affected_VBN
          cancer_NN death_NN rates_NNS ._. It_PRP is_VBZ important_JJ that_IN only_RB baseline_NN
          characteristics_NNS be_VB considered_VBN in_IN investigating_VBG imbalance_NN ._.
          Characteristics_NNP that_WDT could_MD be_VB known_VBN only_RB after_IN
          randomization_NN (_( e_SYM ._. g_SYM ._. number_NN of_IN cancers_NNS diagnosed_VBN ,_, stage_NN ,_,
          age_NN at_IN diagnosis_NN ,_, cure_VB rates_NNS of_IN detected_VBD cancers_NNS )_) are_VBP
          likely_JJ to_TO be_VB biased_VBN because_IN the_DT screening_NN could_MD have_VB
          affected_VBN these_DT characteristics_NNS and_CC the_DT analysis_NN is_VBZ no_RB
          longer_RB "_'' protected_VBN "_'' by_IN randomization_NN ._.
          Randomization_NNP does_VBZ not_RB ,_, however_RB ,_, correct_JJ for_IN another_DT
          type_NN of_IN selection_NN bias_NN ._. Volunteers_NNP who_WP participate_VBP in_IN
          clinical_JJ trials_NNS and_CC who_WP consent_NN to_TO randomization_NN may_MD
          differ_VB from_IN the_DT general_JJ population_NN ._. They_PRP often_RB have_VBP
          better_JJR underlying_VBG health_NN ,_, an_DT effect_NN known_VBN as_IN "_'' healthy_JJ
          volunteer_NN bias_NN ._. "_'' Although_IN we_PRP do_VBP not_RB discuss_VB this_DT bias_NN
          further_RBR ,_, it_PRP should_MD be_VB considered_VBN in_IN planning_NN trial_NN size_NN
          and_CC in_IN trying_VBG to_TO generalize_VB trial_NN results_NNS to_TO the_DT
          population-_NN at-large_JJ ._.
        
      
      
        Methods_NNP
        Our_PRP$ emphasis_NN is_VBZ on_IN simple_JJ methods_NNS ._. Although_IN survival_NN
        analyses_NNS from_IN time_NN of_IN randomization_NN (_( e_SYM ._. g_SYM ._. logrank_NN tests_NNS )_)
        are_VBP sometimes_RB used_VBN ,_, we_PRP focus_VBP on_IN simple_JJ estimates_NNS based_VBN on_IN
        the_DT cumulative_JJ number_NN of_IN cancer_NN deaths_NNS ._. Because_IN cancer_NN
        death_NN is_VBZ a_DT rare_JJ event_NN in_IN asymptomatic_JJ participants_NNS in_IN a_DT
        screening_NN trial_NN ,_, inference_NN based_VBN on_IN survival_NN analysis_NN and_CC
        cumulative_JJ number_NN of_IN cancer_NN deaths_NNS is_VBZ similar_JJ [_NN 2_CD ]_NN ._. We_PRP
        assume_VBP the_DT yearly_JJ numbers_NNS of_IN cancer_NN deaths_NNS follow_VBP a_DT Poisson_NNP
        distribution_NN ,_, which_WDT is_VBZ appropriate_JJ for_IN rare_JJ events_NNS ._.
      
      
        Results_NNS
        
          (_( 1_LS )_) Use_NN death_NN from_IN cancer_NN as_IN the_DT primary_JJ endpoint_NN ,_,
          but_CC review_NN death_NN records_NNS carefully_RB and_CC report_VB all_DT causes_NNS
          of_IN death_NN
          The_DT primary_JJ endpoint_NN of_IN most_JJS cancer_NN screening_NN trials_NNS
          is_VBZ death_NN from_IN cancer_NN ._. Recently_RB Black_NNP [_NN 3_CD ]_NN identified_VBD two_CD
          types_NNS of_IN biases_NNS that_WDT can_MD affect_VB the_DT assessment_NN of_IN the_DT
          cancer_NN death_NN endpoint_NN ._. Sticky-diagnosis_NNP bias_NN arises_VBZ when_WRB
          deaths_NNS from_IN an_DT uncertain_JJ cause_NN are_VBP more_RBR likely_JJ to_TO be_VB
          attributed_VBN to_TO cancer_NN if_IN there_EX was_VBD a_DT previous_JJ diagnosis_NN of_IN
          cancer_NN ,_, especially_RB if_IN the_DT diagnosis_NN was_VBD relatively_RB
          recent_JJ ._. If_IN there_EX were_VBD overdiagnosis_NNS ,_, sticky-diagnosis_JJ
          would_MD induce_VB a_DT higher_JJR cancer_NN death_NN rate_NN in_IN the_DT
          intervention_NN group_NN than_IN actually_RB the_DT case_NN ._. Slippery_NNP
          linkage_NN ,_, the_DT second_JJ type_NN of_IN bias_NN ,_, occurs_VBZ because_IN deaths_NNS
          that_WDT are_VBP caused_VBN or_CC triggered_VBN by_IN screening_VBG ,_, work-up_JJ ,_, or_CC a_DT
          subsequent_JJ therapy_NN (_( e_SYM ._. g_SYM ._. perforation_NN of_IN the_DT colon_NN and_CC
          perhaps_RB cardiovascular_JJ deaths_NNS )_) are_VBP not_RB attributed_VBN to_TO
          screening_NN ._.
          Using_VBG all_DT deaths_NNS as_IN an_DT endpoint_NN avoids_VBZ these_DT biases_NNS
          but_CC leads_VBZ to_TO prohibitive_JJ sample_NN sizes_NNS as_IN shown_VBN in_IN the_DT
          following_VBG calculations_NNS based_VBN on_IN a_DT power_NN of_IN 80_CD %_NN and_CC a_DT
          one-sided_JJ type_NN I_PRP error_NN of_IN 2_CD ._. 5_CD %_NN ._.
          First_LS consider_VB the_DT design_NN of_IN a_DT randomized_JJ trial_NN with_IN a_DT
          cancer_NN death_NN endpoint_NN ._. Under_IN the_DT null_NN hypothesis_NNS ,_, the_DT
          probability_NN of_IN cancer_NN death_NN in_IN each_DT group_NN is_VBZ 
          p_NN ._. Under_IN the_DT alternative_JJ
          hypothesis_NNS the_DT probability_NN of_IN cancer_NN death_NN is_VBZ 
          p_NN in_IN the_DT control_NN group_NN and_CC 
          p-d_JJ in_IN the_DT study_NN group_NN ,_, where_WRB 
          d_SYM is_VBZ the_DT probability_NN of_IN cancer_NN
          death_NN in_IN the_DT control_NN group_NN minus_CC the_DT probability_NN of_IN
          cancer_NN death_NN in_IN the_DT screened_VBD group_NN ._. For_IN computing_NN sample_NN
          size_NN ,_, we_PRP assume_VBP 
          d_SYM is_VBZ positive_JJ ._. Assuming_VBG a_DT Poisson_NNP
          distribution_NN for_IN the_DT number_NN of_IN cancer_NN deaths_NNS ,_, the_DT sample_NN
          size_NN (_( for_IN both_DT groups_NNS combined_VBN )_) for_IN a_DT cancer_NN death_NN
          endpoint_NN is_VBZ
          N_NNP 
          cancer_NN =_SYM 2_CD (_( 1_CD ._. 96_CD Sqrt_NNP [_NN 2_CD v_NN 
          cancerH_NN 0_CD ]_NN +_NN ._. 84_CD Sqrt_NNP [_NN v_NN 
          cancerH_NN 0_CD +_NN v_NN 
          cancerHA_NN ]_NN )_) 2_CD /_NN 
          d_SYM 2_CD ,_,
          where_WRB v_NN 
          cancerH_NN 0_CD =_SYM 
          p_NN and_CC v_NN 
          cancerHA_NN =_SYM 
          p-d_JJ are_VBP the_DT variances_NNS for_IN one_CD
          subject_JJ under_IN the_DT null_NN and_CC alternative_JJ hypotheses_NNS
          respectively_RB ._.
          Now_RB consider_VB the_DT design_NN of_IN a_DT randomized_JJ trial_NN with_IN an_DT
          all_DT death_NN endpoint_NN ._. Let_VB 
          k_NN denote_NN the_DT probability_NN of_IN death_NN
          from_IN causes_NNS unrelated_JJ to_TO either_CC cancer_NN or_CC screening_NN ._.
          Under_IN the_DT null_NN hypothesis_NNS the_DT probability_NN of_IN death_NN from_IN
          all_DT causes_NNS is_VBZ 
          p_NN +_NN 
          k_NN in_IN each_DT group_NN ._. Under_IN the_DT
          alternative_JJ hypothesis_NNS the_DT probability_NN of_IN death_NN from_IN all_DT
          causes_NNS is_VBZ 
          p_NN +_NN 
          k_NN in_IN the_DT control_NN group_NN and_CC (_( 
          p_NN +_NN 
          k_NN )_) -_: (_( 
          d_SYM -_: 
          e_SYM )_) in_IN the_DT screened_VBD group_NN ,_, where_WRB 
          e_SYM is_VBZ the_DT additional_JJ probability_NN of_IN
          non-cancer_JJ deaths_NNS due_JJ to_TO screening_NN ._. Therefore_RB 
          d_SYM -_: 
          e_SYM is_VBZ the_DT probability_NN of_IN death_NN from_IN
          all_DT causes_NNS in_IN the_DT control_NN group_NN minus_CC the_DT probability_NN of_IN
          death_NN from_IN all_DT causes_NNS in_IN the_DT screened_VBD group_NN ._. Assuming_VBG a_DT
          binomial_NN distribution_NN for_IN the_DT number_NN of_IN deaths_NNS from_IN all_DT
          causes_NNS ,_, the_DT sample_NN size_NN (_( for_IN both_DT groups_NNS combined_VBN )_) for_IN an_DT
          all_DT death_NN endpoint_NN is_VBZ
          N_NNP 
          all_DT =_SYM 2_CD (_( 1_CD ._. 96_CD Sqrt_NNP [_NN 2_CD v_NN 
          allH_NN 0_CD ]_NN +_NN ._. 84_CD Sqrt_NNP [_NN v_NN 
          allH_NN 0_CD +_NN v_NN 
          allHA_NN ]_NN )_) 2_CD /_NN (_( 
          d_SYM -_: 
          e_SYM )_) 2_CD ,_,
          where_WRB v_NN 
          allH_NN 0_CD =_SYM (_( 
          p_NN +_NN 
          k_NN )_) (_( 1_CD -_: 
          p_NN -_: 
          k_NN )_) and_CC v_NN 
          allHA_NN =_SYM (_( 
          p_NN +_NN 
          k_NN -_: 
          d_SYM +_NN 
          e_SYM )_) (_( 1_CD -_: 
          p_NN -_: 
          k_NN +_NN 
          d_SYM -_: 
          e_SYM )_) are_VBP the_DT variances_NNS for_IN one_CD
          subject_JJ under_IN the_DT null_NN and_CC alternative_JJ hypotheses_NNS
          respectively_RB ._.
          For_IN purposes_NNS of_IN illustration_NN ,_, suppose_VBP that_DT 
          p_NN =_SYM ._. 005_CD ,_, 
          k_NN =_SYM ._. 15_CD (_( these_DT values_NNS are_VBP based_VBN
          roughly_RB on_IN data_NNS from_IN a_DT colorectal_NN cancer_NN screening_NN trial_NN
          [_NN 4_CD ]_NN )_) ,_, and_CC 
          d_SYM =_SYM ._. 001_CD ._. To_TO minimize_VB N_NNP 
          all_DT ,_, we_PRP set_VBD 
          e_SYM =_SYM 0_CD ._. With_IN these_DT specifications_NNS ,_, a_DT
          study_NN with_IN a_DT cancer_NN death_NN endpoint_NN would_MD require_VB N_NNP 
          cancer_NN =_SYM 150_CD ,_, 000_CD participants_NNS while_IN a_DT
          study_NN with_IN an_DT all_DT death_NN endpoint_NN would_MD require_VB N_NNP 
          all_DT =_SYM 4_CD ._. 1_CD million_CD participants_NNS ._.
          For_IN practical_JJ considerations_NNS ,_, we_PRP recommend_VBP using_VBG
          cancer_NN death_NN as_IN an_DT endpoint_NN with_IN careful_JJ review_NN of_IN the_DT
          death_NN records_NNS to_TO minimize_VB sticky-diagnosis_JJ and_CC slippery_JJ
          linkage_NN bias_NN ._. We_PRP also_RB recommend_VBP that_IN "_'' cancer_NN "_'' deaths_NNS
          include_VBP any_DT non-cancer_JJ deaths_NNS attributable_JJ to_TO screening_NN
          or_CC treatment_NN for_IN the_DT cancer_NN ._.
          We_PRP also_RB recommend_VBP that_IN all_DT deaths_NNS and_CC their_PRP$ causes_NNS be_VB
          reported_VBN ._. If_IN ,_, after_IN adjusting_VBG for_IN multiple_JJ comparisons_NNS ,_,
          there_EX is_VBZ a_DT statistically_RB significant_JJ difference_NN between_IN
          groups_NNS in_IN the_DT estimated_VBN probability_NN of_IN a_DT particular_JJ
          non-cancer_JJ cause_NN of_IN death_NN ,_, the_DT investigators_NNS should_MD
          reexamine_NN the_DT death_NN records_NNS to_TO check_VB for_IN potential_JJ
          biases_NNS ._. If_IN there_EX are_VBP no_DT potential_JJ biases_NNS ,_, the_DT
          investigators_NNS will_MD need_VB to_TO consider_VB the_DT possibility_NN that_DT
          screening_NN or_CC treatment_NN was_VBD responsible_JJ for_IN the_DT
          difference_NN ._.
        
        
          (_( 2_LS )_) Use_NN a_DT simple_JJ "_'' causal_NN "_'' estimate_NN to_TO adjust_VB for_IN
          nonattendance_NN and_CC contamination_NN occurring_VBG immediately_RB
          after_IN randomization_NN
          
            Assumption_NNP 1_CD
            There_EX are_VBP three_CD types_NNS of_IN subjects_NNS :_: always-takers_JJ who_WP
            would_MD receive_VB screening_VBG if_IN randomized_JJ to_TO either_CC group_NN ,_,
            never-takers_JJ who_WP would_MD not_RB receive_VB screening_NN if_IN
            randomized_JJ to_TO either_CC group_NN ,_, and_CC compliers_NNS who_WP would_MD
            receive_VB screening_VBG if_IN randomized_JJ to_TO the_DT intervention_NN
            group_NN but_CC not_RB the_DT control_NN group_NN ._. (_( In_IN other_JJ words_NNS ,_, no_DT
            subjects_NNS would_MD receive_VB screening_VBG if_IN randomized_JJ to_TO the_DT
            control_NN group_NN but_CC not_RB randomized_JJ to_TO the_DT intervention_NN
            group_NN )_) ._.
          
          
            Assumption_NNP 2_CD
            For_IN always-taker_JJ and_CC never-takers_JJ the_DT probability_NN of_IN
            cancer_NN death_NN is_VBZ the_DT same_JJ for_IN each_DT treatment_NN group_NN ._. (_( In_IN
            other_JJ words_NNS ,_, when_WRB a_DT control_NN subject_JJ switches_NNS to_TO
            screening_NN immediately_RB after_IN randomization_NN ,_, the_DT
            screening_NN regime_NN is_VBZ identical_JJ to_TO that_DT in_IN intervention_NN
            group_NN ,_, and_CC when_WRB an_DT intervention_NN subject_JJ immediately_RB
            refuses_VBZ screening_NN ,_, the_DT lack_NN of_IN screening_NN is_VBZ identical_JJ
            to_TO that_DT in_IN the_DT control_NN group_NN ._. )_)
            Unfortunately_RB neither_DT of_IN the_DT assumptions_NNS is_VBZ
            verifiable_JJ ,_, but_CC they_PRP are_VBP reasonable_JJ ,_, and_CC therefore_RB have_VBP
            "_'' face_NN "_'' validity_NN ._. Although_IN the_DT analysis_NN is_VBZ not_RB by_IN
            intent-to-treat_JJ ,_, it_PRP makes_VBZ use_NN of_IN the_DT randomization_NN to_TO
            avoid_VB selection_NN bias_NN ._.
            When_WRB computing_NN f_SYM 
            0_CD and_CC f_SYM 
            1_CD ,_, it_PRP is_VBZ important_JJ to_TO count_VB only_RB
            subjects_VBZ who_WP switch_VBP treatment_NN immediately_RB after_IN
            randomization_NN ,_, so_RB as_RB not_RB to_TO violate_VB Assumption_NNP 2_CD ._. With_IN
            this_DT modification_NN d_SYM 
            causal_NN is_VBZ unbiased_JJ even_RB if_IN
            additional_JJ subjects_NNS switch_VBP treatment_NN later_RB in_IN the_DT
            study_NN ,_, as_IN for_IN example_NN ,_, if_IN some_DT subjects_NNS are_VBP screened_VBD
            initially_RB but_CC refuse_VB subsequent_JJ screenings_NNS ._. The_DT effect_NN
            of_IN later_RB switching_VBG is_VBZ folded_VBN into_IN the_DT interpretation_NN ._.
            Thus_RB d_SYM 
            causal_NN ,_, is_VBZ the_DT estimated_VBN effect_NN of_IN 
            immediately_RB receiving_VBG screening_NN
            with_IN the_DT understanding_NN that_IN the_DT effect_NN is_VBZ likely_JJ
            attenuated_JJ from_IN later_RB switching_NN of_IN treatments_NNS ._.
            In_IN designing_VBG a_DT randomized_JJ trial_NN of_IN cancer_NN screening_NN
            one_PRP should_MD adjust_VB the_DT sample_NN size_NN for_IN anticipated_VBN
            non-attendance_JJ and_CC contamination_NN ._. Suppose_VB the_DT
            anticipated_VBN fraction_NN receiving_VBG immediate_JJ screening_NN is_VBZ f_SYM
            
            0_CD and_CC f_SYM 
            1_CD for_IN the_DT control_NN and_CC intervention_NN
            groups_NNS ,_, respectively_RB ._. As_IN derived_VBN by_IN Zelen_NNP [_NN 11_CD ]_NN ,_, the_DT
            adjusted_VBN sample_NN size_NN is_VBZ the_DT sample_NN size_NN if_IN there_EX were_VBD
            full_JJ attendance_NN and_CC no_DT contamination_NN divided_VBN by_IN (_( f_SYM 
            1_CD -_: f_SYM 
            0_CD )_) 2_CD ._.
          
        
        
          (_( 3_LS )_) Use_NN a_DT simple_JJ adaptive_JJ estimate_NN to_TO adjust_VB for_IN
          dilution_NN following_VBG the_DT last_JJ screen_NN
          In_IN a_DT typical_JJ randomized_JJ trial_NN of_IN cancer_NN screening_NN ,_,
          screening_NN is_VBZ offered_VBN for_IN a_DT limited_JJ time_NN and_CC subjects_NNS are_VBP
          followed_VBN after_IN screening_VBG has_VBZ stopped_VBN ._. This_DT leads_VBZ to_TO a_DT
          dilution_NN of_IN treatment_NN effect_NN ,_, as_IN will_MD be_VB explained_VBN ._.
          Consider_VB a_DT special_JJ baseline_NN variable_JJ B_NNP such_JJ that_IN B_NNP =_SYM 1_CD if_IN
          (_( i_NNP )_) the_DT subject_JJ would_MD not_RB be_VB detected_VBN with_IN cancer_NN 
          if_IN screened_VBD ,_, (_( ii_NN )_) the_DT subject_NN would_MD
          become_VB a_DT cancer_NN case_NN after_IN the_DT time_NN of_IN the_DT last_JJ screen_NN ,_,
          and_CC (_( iii_NN )_) the_DT subject_NN would_MD die_VB from_IN the_DT cancer_NN during_IN
          the_DT follow-up_JJ period_NN ._. Otherwise_RB B_NNP =_SYM 0_CD ._. In_IN other_JJ words_NNS B_NNP =_SYM
          1_CD indicates_VBZ a_DT set_NN of_IN cancer_NN deaths_NNS that_WDT could_MD not_RB have_VB
          benefited_VBN from_IN screening_NN ._. We_PRP can_MD identify_VB subjects_NNS with_IN B_NNP
          =_SYM 1_CD in_IN the_DT screened_VBD group_NN but_CC not_RB in_IN the_DT control_NN group_NN ._.
          Let_VB D_NNP denote_NN the_DT number_NN of_IN subjects_NNS with_IN B_NNP =_SYM 1_CD in_IN the_DT
          screened_VBD group_NN ._. By_IN virtue_NN of_IN the_DT randomization_NN ,_, there_EX
          will_MD be_VB approximately_RB D_NNP subjects_NNS with_IN B_NNP =_SYM 1_CD in_IN the_DT
          control_NN group_NN ._. As_IN the_DT length_NN of_IN follow-up_JJ after_IN the_DT last_JJ
          screening_NN increases_NNS ,_, the_DT amount_NN of_IN dilution_NN D_NNP increases_NNS ,_,
          which_WDT increases_VBZ the_DT variance_NN of_IN the_DT estimated_VBN treatment_NN
          difference_NN ._.
          In_IN estimating_VBG the_DT relative_JJ risk_NN of_IN randomization_NN to_TO
          screening_NN or_CC no_DT screening_NN ,_, the_DT value_NN of_IN D_NNP affects_VBZ the_DT
          point_NN estimate_NN because_IN D_NNP is_VBZ added_VBN to_TO both_DT the_DT numerator_NN
          and_CC denominator_NN ._. But_CC when_WRB estimating_VBG a_DT difference_NN in_IN
          treatment_NN effect_NN between_IN the_DT groups_NNS ,_, the_DT value_NN of_IN D_NNP
          cancels_VBZ ._. Nevertheless_RB ,_, the_DT point_NN estimate_NN of_IN a_DT difference_NN
          in_IN treatment_NN effect_NN will_MD likely_JJ change_VB systematically_RB
          during_IN follow-up_JJ ._. The_DT reason_NN is_VBZ that_IN as_IN follow-up_JJ
          increases_NNS ,_, the_DT point_NN estimate_NN includes_VBZ longer-term_JJ
          effects_NNS of_IN screening_NN on_IN cancer_NN mortality_NN ._. For_IN example_NN ,_,
          suppose_VBP that_DT screening_NN reduces_VBZ cancer_NN mortality_NN up_IN to_TO
          five_CD years_NNS after_IN the_DT last_JJ screening_NN ._. If_IN one_CD used_VBD the_DT
          estimated_VBN difference_NN in_IN cancer_NN mortality_NN at_IN the_DT end_NN of_IN a_DT
          3_CD -_: year_NN follow-up_JJ period_NN ,_, this_DT estimate_NN would_MD likely_RB be_VB
          biased_VBN relative_JJ to_TO the_DT true_JJ difference_NN at_IN 5_CD years_NNS ._. Thus_RB ,_,
          the_DT longer_RBR the_DT longer_RBR the_DT follow-up_JJ period_NN (_( up_IN to_TO some_DT
          point_NN )_) the_DT less_JJR chance_NN for_IN bias_NN due_JJ to_TO excluding_VBG
          long-term_JJ effects_NNS of_IN screening_NN ._. But_CC as_IN mentioned_VBN
          previously_RB ,_, the_DT longer_RBR the_DT follow-up_JJ period_NN the_DT greater_JJR
          the_DT dilution_NN ._. Thus_RB with_IN longer_RBR follow-up_JJ ,_, there_EX is_VBZ a_DT
          variance-bias_JJ tradeoff_NN for_IN estimating_VBG the_DT difference_NN in_IN
          cancer_NN mortality_NN ._.
          Because_IN of_IN this_DT variance-bias_JJ trade-off_NN ,_, the_DT results_NNS
          of_IN a_DT randomized_JJ screening_NN trial_NN vary_VBP with_IN the_DT length_NN of_IN
          follow-up_JJ after_IN the_DT last_JJ screening_NN ._. For_IN example_NN ,_, consider_VB
          data_NNS from_IN the_DT Health_NNP Insurance_NNP Plan_NNP of_IN Greater_NNP New_NNP York_NNP
          (_( HIP_NNP )_) Study_NN [_NN 12_CD ]_NN in_IN which_WDT approximately_RB 62_CD ,_, 000_CD women_NNS
          were_VBD randomized_JJ to_TO either_CC no_DT screening_NN or_CC an_DT invitation_NN
          for_IN four_CD annual_JJ breast_NN cancer_NN screenings_NNS ._. We_PRP estimated_VBD
          the_DT reduction_NN in_IN the_DT probability_NN of_IN cancer_NN death_NN among_IN
          compliers_NNS at_IN years_NNS 5_CD ,_, 10_CD ,_, and_CC 15_CD since_IN randomization_NN
          pretending_VBG each_DT of_IN these_DT times_NNS was_VBD fixed_VBN in_IN advance_NN of_IN
          the_DT study_NN (_( Figure_NN 1_LS )_) ._. At_IN 5_CD and_CC 10_CD years_NNS after_IN
          randomization_NN ,_, the_DT lower_JJR bound_JJ of_IN the_DT 95_CD %_NN confidence_NN
          interval_NN was_VBD above_IN zero_CD ;_: however_RB this_DT was_VBD not_RB the_DT case_NN
          for_IN 15_CD years_NNS after_IN randomization_NN ._. A_DT major_JJ problem_NN is_VBZ how_WRB
          to_TO best_JJS to_TO analyze_VB these_DT data_NNS ._.
          One_CD approach_NN is_VBZ a_DT limited_JJ mortality_NN analysis_NN [_NN 2_CD ]_NN
          that_WDT counts_VBZ cancer_NN deaths_NNS over_IN the_DT entire_JJ follow-up_JJ
          period_NN but_CC only_RB among_IN participants_NNS with_IN cancer_NN up_IN to_TO time_NN
          t_NN 
          catch-up_NN after_IN randomization_NN ._. The_DT time_NN
          t_NN 
          catch-up_NN is_VBZ the_DT time_NN when_WRB the_DT number_NN
          of_IN cases_NNS in_IN the_DT control_NN group_NN first_RB equals_VBZ or_CC surpasses_NNS
          (_( catches-up_JJ to_TO )_) the_DT number_NN of_IN cases_NNS in_IN the_DT intervention_NN
          group_NN ._. The_DT presumption_NN is_VBZ that_IN cases_NNS surfacing_VBG after_IN t_NN 
          catch-up_NN only_RB dilute_VB the_DT estimated_VBN
          effect_NN ._. One_CD problem_NN is_VBZ that_DT t_NN 
          catch-up_NN does_VBZ not_RB occur_VB if_IN there_EX is_VBZ
          overdiagnosis_NNS ._. A_DT related_VBN problem_NN is_VBZ that_DT t_NN 
          catch-up_NN might_MD not_RB occur_VB for_IN a_DT very_RB
          long_JJ time_NN ,_, making_VBG its_PRP$ calculation_NN impractical_JJ ._. Another_DT
          problem_NN is_VBZ that_IN equal_JJ numbers_NNS of_IN cases_NNS in_IN both_DT groups_NNS do_VBP
          not_RB guarantee_VB an_DT unbiased_JJ test_NN [_NN 13_CD ]_NN ._.
          A_DT second_JJ approach_NN is_VBZ to_TO test_VB if_IN screening_NN reduces_VBZ
          cancer_NN mortality_NN rates_NNS using_VBG a_DT special_JJ weighted_JJ logrank_NN
          statistic_NN for_IN survival_NN data_NNS [_NN 14_CD 15_CD ]_NN ._.
          A_DT third_JJ approach_NN is_VBZ to_TO select_VB follow-up_JJ times_NNS based_VBN on_IN
          maximum_NN power_NN given_VBN parameter_NN estimates_NNS from_IN previous_JJ
          trials_NNS and_CC the_DT effect_NN size_NN that_IN one_PRP would_MD like_VB to_TO detect_VB
          [_NN 16_CD ]_NN ._.
          As_IN a_DT fourth_JJ approach_NN ,_, we_PRP propose_VBP a_DT simple_JJ adaptive_JJ
          method_NN to_TO compute_VB estimates_NNS and_CC confidence_NN intervals_NNS for_IN
          the_DT effect_NN of_IN screening_NN when_WRB there_EX is_VBZ follow-up_JJ after_IN the_DT
          last_JJ screen_NN ._. To_TO the_DT best_JJS of_IN our_PRP$ knowledge_NN this_DT method_NN is_VBZ
          new_JJ to_TO the_DT screening_NN literature_NN ._. In_IN this_DT analysis_NN ,_,
          "_'' adaptive_JJ "_'' refers_VBZ to_TO using_VBG the_DT data_NNS to_TO select_VB the_DT
          follow-up_JJ time_NN ,_, with_IN appropriate_JJ adjustment_NN in_IN computing_VBG
          confidence_NN intervals_NNS ._. Let_VB p_NN 
          0_CD (_( t_NN )_) and_CC p_NN 
          1_CD (_( t_NN )_) denote_NN the_DT cumulative_JJ fraction_NN
          of_IN subjects_NNS who_WP die_VBP from_IN cancer_NN up_IN to_TO time_NN t_NN in_IN the_DT
          control_NN and_CC intervention_NN groups_NNS ,_, respectively_RB ._. Letting_VBG n_NN
          denote_NN the_DT number_NN of_IN subjects_NNS in_IN each_DT group_NN ,_, we_PRP
          define_VB
          z_SYM (_( t_NN )_) =_SYM (_( p_NN 
          0_CD (_( t_NN )_) -_: p_NN 
          1_CD (_( t_NN )_) )_) /_NN (_( Sqrt_NNP [_NN p_NN 
          0_CD (_( t_NN )_) +_NN p_NN 
          1_CD (_( t_NN )_) ]_NN /_NN n_NN )_) ,_,
          which_WDT is_VBZ the_DT difference_NN between_IN p_NN 
          0_CD (_( t_NN )_) and_CC p_NN 
          1_CD (_( t_NN )_) divided_VBN by_IN its_PRP$ standard_JJ error_NN ,_,
          i_NNP ._. e_SYM ._. ,_, the_DT z-value_JJ associated_VBN with_IN a_DT normally_RB distributed_VBN
          random_JJ variable_NN ._. If_IN screening_NN reduces_VBZ the_DT probability_NN of_IN
          cancer_NN death_NN ,_, z_SYM (_( t_NN )_) will_MD generally_RB increase_VB over_IN the_DT time_NN
          t_NN that_DT screening_NN is_VBZ offered_VBN and_CC perhaps_RB a_DT little_JJ longer_RBR ._.
          However_RB at_IN some_DT point_NN after_IN screening_VBG has_VBZ stopped_VBN z_SYM (_( t_NN )_)
          will_MD generally_RB decrease_VB over_IN time_NN because_IN p_NN 
          0_CD (_( t_NN )_) and_CC p_NN 
          1_CD (_( t_NN )_) will_MD each_DT increase_VB by_IN roughly_RB
          the_DT same_JJ amount_NN from_IN cases_NNS that_WDT arose_VBD after_IN screening_NN had_VBD
          stopped_VBN (_( i_NNP ._. e_SYM ._. the_DT effect_NN of_IN dilution_NN )_) ._. See_VB also_RB [_NN 16_CD ]_NN
          for_IN a_DT justification_NN of_IN this_DT behavior_NN of_IN z_SYM (_( t_NN )_) based_VBN on_IN
          modeling_NN natural_JJ history_NN in_IN breast_NN cancer_NN screening_NN ._. We_PRP
          assume_VBP that_DT screening_NN does_VBZ not_RB cause_VB cancer_NN deaths_NNS ;_:
          otherwise_RB it_PRP would_MD be_VB possible_JJ for_IN z_SYM (_( t_NN )_) to_TO decrease_VB for_IN
          reasons_NNS other_JJ than_IN dilution_NN ._. This_DT motivates_NNS selecting_VBG as_IN
          the_DT follow-up_JJ time_NN the_DT time_NN t_NN *_NN that_IN maximizes_NNS z_SYM (_( t_NN )_) with_IN
          an_DT estimated_VBN effect_NN of_IN
          d_SYM 
          causal_NN (_( t_NN *_NN )_) =_SYM (_( p_NN 
          1_CD (_( t_NN *_NN )_) -_: p_NN 
          0_CD (_( t_NN *_NN )_) )_) /_NN (_( f_SYM 
          1_CD -_: f_SYM 
          0_CD )_) ._.
          We_PRP interpret_VBP d_SYM 
          causal_NN (_( t_NN *_NN )_) as_IN the_DT effect_NN of_IN receiving_VBG
          screening_NN in_IN compliers_NNS before_IN dilution_NN attenuates_NNS any_DT
          effects_NNS ._. For_IN d_SYM 
          causal_NN (_( t_NN *_NN )_) to_TO be_VB correctly_RB
          interpretable_JJ as_IN an_DT effect_NN of_IN receiving_VBG screening_NN ,_, we_PRP
          assume_VBP that_IN after_IN perhaps_RB some_DT initial_JJ fluctuations_NNS p_NN 
          1_CD (_( t_NN )_) -_: p_NN 
          0_CD (_( t_NN )_) is_VBZ generally_RB increasing_VBG or_CC
          constant_JJ over_IN time_NN until_IN dilution_NN reduces_VBZ z_SYM (_( t_NN )_) ._. In_IN other_JJ
          words_NNS ,_, although_IN there_EX may_MD be_VB a_DT brief_JJ increase_NN in_IN cancer_NN
          deaths_NNS due_JJ to_TO screening_NN soon_RB after_IN the_DT start_NN of_IN the_DT
          trial_NN ,_, we_PRP assume_VBP that_IN after_IN screening_VBG stops_VBZ ,_, screening_NN
          does_VBZ not_RB start_VB causing_VBG more_JJR cancer_NN deaths_NNS than_IN in_IN the_DT
          control_NN group_NN ._. Otherwise_RB we_PRP might_MD incorrectly_RB attribute_VB a_DT
          small_JJ difference_NN between_IN p_NN 
          1_CD (_( t_NN )_) -_: p_NN 
          0_CD (_( t_NN )_) to_TO the_DT effect_NN of_IN dilution_NN when_WRB
          it_PRP is_VBZ due_JJ to_TO delayed_VBN harms_NNS of_IN screening_NN and_CC early_JJ
          treatment_NN ._.
          Computing_NNP confidence_NN intervals_NNS by_IN ignoring_VBG the_DT fact_NN
          that_DT t_NN *_NN was_VBD based_VBN on_IN the_DT data_NNS represents_VBZ "_'' cutpoint_NN
          optimization_NN "_'' [_NN 17_CD ]_NN and_CC is_VBZ thus_RB inappropriate_JJ ._. To_TO
          compute_VB a_DT confidence_NN interval_NN for_IN d_SYM 
          causal_NN (_( t_NN *_NN )_) that_IN accounts_NNS for_IN the_DT
          adaptive_JJ choice_NN of_IN t_NN *_NN ,_, we_PRP use_VBP the_DT following_VBG bootstrap_NN [_NN
          18_CD ]_NN approach_NN ._.
          For_IN purposes_NNS of_IN illustration_NN we_PRP applied_VBD this_DT method_NN to_TO
          data_NNS in_IN [_NN 2_CD ]_NN on_IN breast_NN cancer_NN screening_NN from_IN the_DT Health_NNP
          Insurance_NNP Plan_NNP of_IN Greater_NNP of_IN New_NNP York_NNP (_( HIP_NNP )_) Study_NN ._. For_IN
          each_DT year_NN after_IN randomization_NN we_PRP randomly_RB generated_VBD a_DT
          number_NN of_IN cancer_NN deaths_NNS in_IN each_DT group_NN based_VBN on_IN a_DT Poisson_NNP
          distribution_NN with_IN mean_NN value_NN equal_JJ to_TO the_DT observed_VBN number_NN
          of_IN deaths_NNS in_IN that_DT year_NN and_CC group_NN ._. From_IN these_DT randomly_RB
          generated_VBN data_NNS we_PRP computed_JJ t_NN *_NN and_CC d_SYM 
          causal_NN (_( t_NN *_NN )_) ._. We_PRP repeated_VBD this_DT
          calculation_NN 10_CD ,_, 000_CD times_NNS to_TO obtain_VB distributions_NNS for_IN t_NN *_NN
          and_CC d_SYM 
          causal_NN (_( t_NN *_NN )_) ._. The_DT mean_JJ value_NN of_IN these_DT
          distributions_NNS is_VBZ the_DT estimate_NN and_CC the_DT lower_JJR 2_CD ._. 5_CD %_NN and_CC
          upper_JJ 97_CD ._. 5_LS %_NN quantiles_NNS gives_VBZ the_DT 95_CD %_NN confidence_NN interval_NN ._.
          For_IN t_NN *_NN we_PRP obtained_VBD an_DT estimate_NN of_IN 7_CD ._. 3_CD years_NNS with_IN a_DT 95_CD %_NN
          confidence_NN interval_NN of_IN 4_CD to_TO 13_CD years_NNS ._. For_IN d_SYM 
          causal_NN (_( t_NN *_NN )_) ,_, the_DT estimate_NN and_CC 95_CD %_NN
          confidence_NN interval_NN are_VBP shown_VBN in_IN Figure_NN 1_CD ._.
          To_TO compute_VB sample_NN size_NN for_IN a_DT randomized_JJ trial_NN with_IN
          follow-up_JJ after_IN the_DT last_JJ screening_NN ,_, we_PRP propose_VBP the_DT
          following_VBG approach_NN to_TO account_VB for_IN the_DT adaptive_JJ nature_NN of_IN
          the_DT test_NN statistic_NN ._. The_DT first_JJ step_NN is_VBZ to_TO create_VB
          anticipated_VBN data_NNS with_IN 
          m_NN subjects_NNS per_IN group_NN under_IN the_DT null_NN
          and_CC alternative_JJ hypotheses_NNS ._. The_DT second_JJ step_NN is_VBZ to_TO treat_VB
          the_DT anticipated_VBN data_NN as_IN observed_VBN data_NNS and_CC compute_VB
          bootstrap_NN estimates_NNS of_IN the_DT variance_NN ._. Let_VB 
          v_NN 
          
            adpativeH_NN 0_CD 
           and_CC 
          v_NN 
          
            adaptiveHA_NN 
           denote_NN the_DT bootstrap_NN estimate_NN of_IN the_DT variance_NN
          divided_VBN by_IN 
          m_NN under_IN the_DT null_NN and_CC alternative_JJ
          hypothesis_NNS ,_, respectively_RB ._. In_IN other_JJ words_NNS 
          v_NN 
          
            adpativeH_NN 0_CD 
           and_CC 
          v_NN 
          
            adaptiveHA_NN 
           are_VBP the_DT bootstrap_NN estimates_NNS of_IN variance_NN for_IN one_CD
          subject_JJ ._. The_DT sample_NN size_NN with_IN cancer_NN death_NN endpoint_NN and_CC
          adjustment_NN for_IN non-attendance_JJ and_CC contamination_NN is_VBZ
          N_NNP 
          adaptive_JJ =_SYM 2_CD (_( (_( 1_CD ._. 96_CD Sqrt_NNP [_NN 2_CD 
          v_NN 
          
            adpativeH_NN 0_CD 
           ]_NN +_NN ._. 84_CD Sqrt_NNP [_NN 
          v_NN 
          
            adpativeH_NN 0_CD 
           +_NN 
          v_NN 
          
            adaptiveHA_NN 
           ]_NN )_) 2_CD /_NN 
          d_SYM 2_LS )_) /_NN (_( f_SYM 
          1_CD -_: f_SYM 
          0_CD )_) 2_CD ._.
          One_CD other_JJ issue_NN in_IN design_NN is_VBZ the_DT duration_NN of_IN
          screening_NN ._. It_PRP should_MD be_VB sufficiently_RB long_RB so_IN that_IN any_DT
          reduction_NN in_IN cancer_NN mortality_NN would_MD be_VB apparent_JJ before_IN
          dilution_NN has_VBZ an_DT effect_NN ._.
        
      
      
        Discussion_NNP
        In_IN cancer_NN therapy_NN trials_NNS ,_, the_DT standard_JJ statistical_JJ
        approach_NN is_VBZ an_DT intent-to-treat_JJ analysis_NN using_VBG a_DT
        non-adaptive_JJ statistic_NN with_IN an_DT all_DT death_NN endpoint_NN ._. Why_WRB are_VBP
        we_PRP advocating_VBG a_DT different_JJ approach_NN for_IN cancer_NN screening_NN
        trials_NNS ?_. On_IN a_DT fundamental_JJ level_NN ,_, cancer-screening_JJ trials_NNS
        differ_VBP from_IN therapy_NN trials_NNS because_IN of_IN the_DT high_JJ amount_NN of_IN
        "_'' noise_NN "_'' relative_JJ to_TO the_DT "_'' signal_NN "_'' of_IN screening_NN effect_NN ._. This_DT
        "_'' noise_NN "_'' arises_VBZ because_IN cancer_NN deaths_NNS are_VBP rare_JJ relative_NN to_TO
        all_DT deaths_NNS ,_, non-attendance_JJ and_CC contamination_NN immediately_RB
        after_IN randomization_NN are_VBP common_JJ ,_, and_CC discontinuation_NN of_IN
        screening_NN leads_VBZ to_TO a_DT dilution_NN of_IN cancer_NN deaths_NNS due_JJ to_TO cases_NNS
        arising_VBG after_IN screening_VBG has_VBZ stopped_VBN ._.
        With_IN the_DT proposed_VBN analysis_NN ,_, we_PRP can_MD reduce_VB the_DT "_'' noise_NN "_'' at_IN
        the_DT "_'' price_NN "_'' of_IN a_DT few_JJ reasonable_JJ assumptions_NNS ._. In_IN using_VBG a_DT
        cancer_NN death_NN endpoint_NN with_IN careful_JJ review_NN of_IN death_NN records_NNS ,_,
        we_PRP assume_VBP that_IN deaths_NNS caused_VBN by_IN screening_VBG via_IN unanticipated_JJ
        pathways_NNS ,_, such_JJ as_IN cardiovascular_JJ disease_NN ,_, are_VBP correctly_RB
        attributed_VBN to_TO screening_NN ._. In_IN using_VBG the_DT simple_JJ "_'' causal_NN "_'' model_NN
        to_TO adjust_VB for_IN nonattendance_NN and_CC contamination_NN ,_, we_PRP assume_VBP
        that_IN (_( i_NNP )_) a_DT subject_JJ who_WP switches_VBZ treatment_NN immediately_RB after_IN
        randomization_NN does_VBZ in_IN fact_NN receive_VBP the_DT same_JJ treatment_NN as_IN in_IN
        the_DT other_JJ treatment_NN group_NN ,_, and_CC (_( ii_NN )_) no_DT subject_NN would_MD
        receive_VB screening_VBG outside_IN the_DT trial_NN if_IN randomized_JJ to_TO the_DT
        control_NN group_NN 
        and_CC refuse_VB screening_NN if_IN randomized_JJ to_TO
        the_DT intervention_NN group_NN ._. In_IN using_VBG the_DT adaptive_JJ statistic_NN to_TO
        estimate_VB the_DT effect_NN of_IN screening_NN in_IN a_DT trial_NN with_IN follow-up_JJ
        after_IN the_DT end_NN of_IN screening_NN ,_, we_PRP assume_VBP that_DT screening_NN does_VBZ
        not_RB increase_VB cancer_NN mortality_NN after_IN some_DT point_NN in_IN time_NN ._.
        Even_RB with_IN the_DT proposed_VBN method_NN for_IN reducing_VBG "_'' noise_NN "_'' ,_, the_DT
        sample_NN sizes_NNS for_IN randomized_JJ cancer-screening_JJ trials_NNS are_VBP
        substantial_JJ ,_, typically_RB requiring_VBG tens_NNS of_IN thousands_NNS of_IN
        subjects_NNS ._. Thus_RB randomized_JJ screening_NN trials_NNS should_MD only_RB be_VB
        undertaken_VBN when_WRB there_EX is_VBZ strong_JJ preliminary_JJ evidence_NN for_IN a_DT
        potential_JJ benefit_NN of_IN screening_NN that_WDT could_MD outweigh_VB
        attendant_NN harms_NNS ._. In_IN this_DT regard_NN ,_, it_PRP is_VBZ important_JJ to_TO have_VB a_DT
        well-designed_JJ strategy_NN for_IN selecting_VBG the_DT most_RBS promising_JJ
        early_JJ detection_NN markers_NNS for_IN evaluation_NN in_IN a_DT randomized_JJ
        cancer-screening_JJ trial_NN [_NN 19_CD 20_CD 21_CD ]_NN ._.
        Our_PRP$ focus_NN has_VBZ been_VBN on_IN randomized_JJ trials_NNS for_IN evaluating_VBG
        the_DT efficacy_NN of_IN cancer_NN screening_NN and_CC the_DT attendant_NN harms_NNS ._.
        However_RB observational_NN studies_NNS have_VBP a_DT role_NN particularly_RB when_WRB
        investigating_VBG secondary_JJ questions_NNS involving_VBG the_DT effect_NN of_IN
        age_NN to_TO begin_VB screening_NN ,_, interval_NN between_IN screenings_NNS ,_, or_CC
        small_JJ changes_NNS in_IN the_DT screening_NN modality_NN ._. Case-control_NNP
        studies_NNS are_VBP applicable_JJ with_IN special_JJ considerations_NNS for_IN
        cancer_NN screening_NN [_NN 22_CD ]_NN ._. Periodic_NNP Screening_NNP Evaluation_NNP
        (_( PSE_NNP )_) is_VBZ a_DT method_NN for_IN using_VBG data_NNS from_IN subjects_NNS of_IN various_JJ
        age_NN who_WP receive_VBP at_IN least_JJS two_CD regularly_RB scheduled_VBN screenings_NNS
        to_TO estimate_VB the_DT reduction_NN in_IN cancer_NN mortality_NN from_IN periodic_JJ
        screening_NN over_IN a_DT range_NN of_IN ages_NNS [_NN 23_CD 24_CD ]_NN ._. The_DT main_JJ
        assumptions_NNS of_IN PSE_NNP are_VBP (_( 1_LS )_) once_RB a_DT cancer_NN is_VBZ detectable_JJ on_IN
        screening_NN it_PRP would_MD be_VB detectable_JJ on_IN later_JJ screenings_NNS (_( 2_LS )_)
        given_VBN age_NN ,_, year_NN of_IN birth_NN adds_VBZ no_DT information_NN for_IN predicting_VBG
        the_DT detection_NN rate_NN on_IN the_DT first_JJ screen_NN ,_, (_( 3_LS )_) no_DT selection_NN
        bias_NN in_IN using_VBG refusers_NNS to_TO estimate_VB survival_NN from_IN detection_NN
        in_IN the_DT absence_NN of_IN screening_NN ._. The_DT paired_VBN availability_NN design_NN
        (_( PAD_NNP )_) is_VBZ a_DT method_NN for_IN combining_VBG data_NNS from_IN various_JJ
        before-and-after_JJ studies_NNS that_WDT adjusts_VBZ for_IN different_JJ
        fraction_NN receiving_VBG the_DT intervention_NN in_IN a_DT manner_NN similar_JJ to_TO
        that_DT for_IN nonattendance_NN and_CC contamination_NN [_NN 25_CD ]_NN ._. For_IN
        applications_NNS to_TO screening_NN ,_, PAD_NNP requires_VBZ a_DT well-defined_JJ
        geographic_JJ region_NN in_IN which_WDT screening_NN has_VBZ been_VBN introduced_VBN ,_,
        with_IN little_JJ in-_NN or_CC -_: out-_NN migration_NN and_CC no_DT other_JJ changes_NNS
        over_IN time_NN that_WDT would_MD affect_VB the_DT endpoint_NN of_IN cancer_NN
        mortality_NN ._.
        We_PRP emphasized_VBD estimating_VBG the_DT reduction_NN (_( if_IN any_DT )_) in_IN
        cancer_NN deaths_NNS due_JJ to_TO screening_NN ._. For_IN a_DT balanced_JJ evaluation_NN ,_,
        one_PRP should_MD also_RB estimate_VB the_DT probability_NN of_IN an_DT unnecessary_JJ
        biopsy_NN [_NN 23_CD ]_NN and_CC other_JJ harms_VBZ attendant_NN to_TO screening_NN and_CC
        interventions_NNS triggered_VBN by_IN the_DT screening_NN process_NN ._.
      
      
        Conclusion_NNP
        The_DT proposed_VBN guidelines_NNS combine_VBP recent_JJ methodological_JJ
        work_NN on_IN screening_NN endpoints_NNS and_CC noncompliance_NN /_NN contamination_NN
        with_IN a_DT new_JJ adaptive_JJ method_NN to_TO adjust_VB for_IN dilution_NN in_IN a_DT
        study_NN where_WRB follow-up_JJ continues_VBZ after_IN the_DT last_JJ screen_NN ._. They_PRP
        should_MD greatly_RB help_VB investigators_NNS design_NN and_CC analyze_VB
        randomized_JJ trials_NNS for_IN the_DT early_JJ detection_NN of_IN cancer_NN ._.
        Because_IN the_DT assumptions_NNS are_VBP reasonable_JJ ,_, we_PRP recommend_VBP these_DT
        guidelines_NNS as_IN one_CD of_IN the_DT primary_JJ analyses_NNS ._.
      
      
        Authors_NNP '_'' Contributions_NNP
        SGB_NNP wrote_VBD an_DT initial_JJ draft_NN and_CC BSK_NNP and_CC PCP_NNP made_VBD
        important_JJ improvements_NNS ._. All_DT authors_NNS read_VBP and_CC approved_VBD the_DT
        final_JJ manuscript_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
